What is Hexagon Bio?
Hexagon Bio operates at the intersection of data science, genomics, and synthetic biology. The company distinguishes itself through a novel platform that decodes natural product evolution, enabling the discovery of potent small molecules directly from fungal genomes. By integrating automation and advanced computational biology, Hexagon Bio identifies protein targets with high precision, effectively streamlining the path from genomic data to viable therapeutic solutions for complex human diseases. This interdisciplinary methodology places the firm at the forefront of the next generation of drug discovery, where biological insights are transformed into scalable medical interventions.
How much funding has Hexagon Bio raised?
Hexagon Bio has raised a total of $185.3M across 3 funding rounds:
Other Financing Round
$61M
Series A
$47M
Series B
$77.3M
Other Financing Round (2021): $61M with participation from SoftBank Group Corp, Nextech Invest, The Column Group, Two Sigma Ventures, 8VC, and Casdin Capital
Series A (2022): $47M led by The Column Group, Two Sigma Ventures, and 8VC
Series B (2023): $77.3M supported by The Column Group, Two Sigma Ventures, 8VC, and NexTech
Key Investors in Hexagon Bio
The Column Group
A venture ecosystem focused on advancing scientific innovation in the life sciences sector, providing comprehensive support from inception to exit.
Two Sigma Ventures
An early-stage venture capital firm that invests in transformative companies leveraging information growth, computing power, and data-driven innovation.
8VC
A leading technology investment firm that backs industry-transforming companies, with a specific focus on smart enterprise platforms and Bio-IT.
What's next for Hexagon Bio?
Looking ahead, Hexagon Bio is poised to leverage its recent capital infusion to scale its discovery engine and expand its therapeutic portfolio. The strategic focus will likely center on validating lead candidates in preclinical models and strengthening its intellectual property moat. As the company transitions into a more mature operational phase, the emphasis will shift toward establishing key partnerships and potentially initiating early-stage clinical trials. With the continued support of its venture partners, Hexagon Bio is well-positioned to redefine the standards of small-molecule development in the life sciences sector.
See full Hexagon Bio company page
